WHO has recommended lenacapavir, a twice-yearly injectable PrEP drug, for global HIV prevention. Announced at IAS 2025, this long-acting option offers an alternative to daily pills, especially for those facing adherence issues. Despite its high cost, WHO urges immediate integration into HIV programs, citing its near-complete prevention in trials.